132 related articles for article (PubMed ID: 33058716)
1. Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy.
Bröckelmann PJ; Müller H; Guhl T; Behringer K; Fuchs M; Moccia AA; Rank A; Soekler M; Vieler T; Pabst T; Baues C; von Tresckow B; Borchmann P; Engert A
J Clin Oncol; 2021 Jan; 39(2):107-115. PubMed ID: 33058716
[TBL] [Abstract][Full Text] [Related]
2. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
Skoetz N; Will A; Monsef I; Brillant C; Engert A; von Tresckow B
Cochrane Database Syst Rev; 2017 May; 5(5):CD007941. PubMed ID: 28541603
[TBL] [Abstract][Full Text] [Related]
3. Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial.
Russell J; Collins A; Fowler A; Karanth M; Saha C; Docherty S; Padayatty J; Maw K; Lentell I; Cooke L; Hodson A; Shah N; Sadullah S; Grigoropoulos N; Qian W; Kirkwood AA; Uttenthal BJ; Johnson P; Follows GA
Ann Hematol; 2021 Apr; 100(4):1049-1058. PubMed ID: 33641019
[TBL] [Abstract][Full Text] [Related]
4. Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.
Franklin J; Eichenauer DA; Becker I; Monsef I; Engert A
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD008814. PubMed ID: 28901021
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma.
Federico M; Fortpied C; Stepanishyna Y; Gotti M; van der Maazen R; Cristinelli C; Re A; Plattel W; Lazarovici J; Merli F; Specht L; Schiano de Colella JM; Hutchings M; Versari A; Edeline V; Stamatoulas A; Girinsky T; Ricardi U; Aleman B; Meulemans B; Tonino S; Raemaekers J; André M
J Clin Oncol; 2024 Jan; 42(1):19-25. PubMed ID: 37967311
[No Abstract] [Full Text] [Related]
6. Real-life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience.
Zilioli VR; Cencini E; Lorenzo S; Pezzullo L; Merli M; Rivellini F; Muzi C; Emiliano B; Marcheselli L; Luminari S
Hematol Oncol; 2024 May; 42(3):e3273. PubMed ID: 38661120
[TBL] [Abstract][Full Text] [Related]
7. Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.
Henderson TO; Parsons SK; Wroblewski KE; Chen L; Hong F; Smith SM; McNeer JL; Advani RH; Gascoyne RD; Constine LS; Horning S; Bartlett NL; Shah B; Connors JM; Leonard JI; Kahl BS; Kelly KM; Schwartz CL; Li H; Friedberg JW; Friedman DL; Gordon LI; Evens AM
Cancer; 2018 Jan; 124(1):136-144. PubMed ID: 28902390
[TBL] [Abstract][Full Text] [Related]
8. Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study.
Barrington SF; Phillips EH; Counsell N; Hancock B; Pettengell R; Johnson P; Townsend W; Culligan D; Popova B; Clifton-Hadley L; McMillan A; Hoskin P; O'Doherty MJ; Illidge T; Radford J
J Clin Oncol; 2019 Jul; 37(20):1732-1741. PubMed ID: 31112475
[TBL] [Abstract][Full Text] [Related]
9. Patterns of relapse from a phase 3 Study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children's Oncology Group.
Dharmarajan KV; Friedman DL; Schwartz CL; Chen L; FitzGerald TJ; McCarten KM; Kessel SK; Iandoli M; Constine LS; Wolden SL
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):60-6. PubMed ID: 25542311
[TBL] [Abstract][Full Text] [Related]
10. Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies.
Eichenauer DA; Bühnen I; Baues C; Kobe C; Kaul H; Greil R; Moccia A; Zijlstra JM; Hertenstein B; Topp MS; Just M; von Tresckow B; Eich HT; Fuchs M; Dietlein M; Hartmann S; Engert A; Borchmann P
Blood; 2023 Aug; 142(6):553-560. PubMed ID: 37257195
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial.
Luminari S; Fossa A; Trotman J; Molin D; d'Amore F; Enblad G; Berkahn L; Barrington SF; Radford J; Federico M; Kirkwood AA; Johnson PWM
J Clin Oncol; 2024 Jan; 42(1):13-18. PubMed ID: 37883739
[No Abstract] [Full Text] [Related]
12. Improved survival of children and adolescents with classical Hodgkin lymphoma treated on a harmonised protocol in South Africa.
Geel J; van Zyl A; Plessis JD; Hendricks M; Goga Y; Carr A; Neethling B; Hramyka A; Omar F; Mathew R; Louw L; Naidoo T; Ngcana T; Schickerling T; Netshituni V; Madzhia E; du Plessis L; Kelsey T; Ballot DE; Metzger ML
Pediatr Blood Cancer; 2024 Jan; 71(1):e30712. PubMed ID: 37814417
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma.
Chow VA; Rajendran JG; Fisher DR; Appelbaum FR; Cassaday RD; Martin PS; Holmberg LA; Gooley TA; Stevenson PA; Pagel JM; Green DJ; Press OW; Gopal AK
Am J Hematol; 2020 Jul; 95(7):775-783. PubMed ID: 32243637
[TBL] [Abstract][Full Text] [Related]
14. Hodgkin Lymphoma in Adults.
Bröckelmann PJ; Eichenauer DA; Jakob T; Follmann M; Engert A; Skoetz N
Dtsch Arztebl Int; 2018 Aug; 115(31-32):535-540. PubMed ID: 30149835
[TBL] [Abstract][Full Text] [Related]
15. Targeted radiotherapy for early-stage, low-risk pediatric Hodgkin lymphoma slow early responders: a COG AHOD0431 analysis.
Parekh A; Keller FG; McCarten KM; Kessel S; Cho S; Pei Q; Wu Y; Castellino SM; Constine LS; Schwartz CL; Hodgson D; Kelly KM; Hoppe BS
Blood; 2022 Sep; 140(10):1086-1093. PubMed ID: 35763667
[TBL] [Abstract][Full Text] [Related]
16. The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients.
Ghesquières H; Krzisch D; Nicolas-Virelizier E; Kanoun S; Gac AC; Guidez S; Touati M; Laribi K; Morschhauser F; Bonnet C; Waultier-Rascalou A; Orsini-Piocelle F; André M; Fournier M; Morand F; Berriolo-Riedinger A; Burroni B; Damotte D; Traverse-Glehen A; Quittet P; Casasnovas O
Blood; 2024 Mar; 143(11):983-995. PubMed ID: 37979133
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant.
Tun AM; Wang Y; Matin A; Inwards DJ; Habermann TM; Micallef I; Johnston PB; Porrata L; Paludo J; Bisneto JV; Rosenthal A; Tun HW; Cerhan JR; Witzig TE; Nowakowski GS; Ansell SM
Hemasphere; 2023 Apr; 7(4):e869. PubMed ID: 37034004
[TBL] [Abstract][Full Text] [Related]
18. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study.
London WB; Frantz CN; Campbell LA; Seeger RC; Brumback BA; Cohn SL; Matthay KK; Castleberry RP; Diller L
J Clin Oncol; 2010 Aug; 28(24):3808-15. PubMed ID: 20660830
[TBL] [Abstract][Full Text] [Related]
19. Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma.
Scott DW; Chan FC; Hong F; Rogic S; Tan KL; Meissner B; Ben-Neriah S; Boyle M; Kridel R; Telenius A; Woolcock BW; Farinha P; Fisher RI; Rimsza LM; Bartlett NL; Cheson BD; Shepherd LE; Advani RH; Connors JM; Kahl BS; Gordon LI; Horning SJ; Steidl C; Gascoyne RD
J Clin Oncol; 2013 Feb; 31(6):692-700. PubMed ID: 23182984
[TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies.
Viviani S; Vanazzi A; Frassoni S; Rusconi C; Rossi A; Romano A; Patti C; Schiavotto C; Sorasio R; Marasco V; Lissandrini L; Rapezzi D; Gottardi D; Cocito F; Mulè A; Leotta S; Gini G; Sorio M; Derenzini E; Rambaldi A; Bagnardi V; Tarella C
Leuk Lymphoma; 2024 Apr; 65(4):460-471. PubMed ID: 38164812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
